KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $5.0 billion.

  • Pfizer's Accounts Payables fell 545.73% to $5.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 billion, marking a year-over-year decrease of 545.73%. This contributed to the annual value of $5.6 billion for FY2024, which is 1605.07% down from last year.
  • Latest data reveals that Pfizer reported Accounts Payables of $5.0 billion as of Q3 2025, which was down 545.73% from $5.2 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's Accounts Payables registered a high of $6.8 billion during Q4 2022, and its lowest value of $4.1 billion during Q2 2021.
  • Over the past 5 years, Pfizer's median Accounts Payables value was $5.5 billion (recorded in 2022), while the average stood at $5.5 billion.
  • As far as peak fluctuations go, Pfizer's Accounts Payables skyrocketed by 4347.12% in 2022, and later plummeted by 1605.07% in 2024.
  • Over the past 5 years, Pfizer's Accounts Payables (Quarter) stood at $5.6 billion in 2021, then grew by 22.07% to $6.8 billion in 2022, then fell by 1.45% to $6.7 billion in 2023, then decreased by 16.05% to $5.6 billion in 2024, then fell by 10.81% to $5.0 billion in 2025.
  • Its Accounts Payables was $5.0 billion in Q3 2025, compared to $5.2 billion in Q2 2025 and $5.2 billion in Q1 2025.